Results 51 to 60 of about 4,843 (156)

Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective

Global & Regional Health Technology Assessment, 2018
Recent evidence suggests that adding protein convertase subtilisin/kexin type 9 inhibitors to current lipid-lowering therapies may result in unprecedented reductions in low-density lipoprotein cholesterol.
Alessia Marocco, Sanja Stanisic, Francesca Fanelli, Francesco Damele, Furio Colivicchi   +4 more
doaj   +1 more source

Leptin–cholesterol crosstalk in pregnancy: Mechanistic implications for placental function and cardiometabolic programming

Experimental Physiology, EarlyView.
Abstract Pregnancy requires the coordinated maternal reorganization of lipid and endocrine pathways to sustain fetal growth and anticipate neonatal nutrition. Leptin, produced by adipose tissue and the placenta, acts as an integrative signal linking maternal energy status with trophoblast function and vascular adaptation, while cholesterol provides ...
Julio Flores, Diego Gumera, Andreina Arias, Cristián A. Amador, María José Yañez   +4 more
wiley   +1 more source

Efficacy and Safety of Oral Non‐Statin Lipid‐Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
A network meta‐analysis of 43 randomized trials showed that oral combination therapies, particularly obicetrapib plus ezetimibe and bempedoic acid plus ezetimibe, achieved the greatest LDL‐C reduction with reassuring safety profiles, supporting their use as effective oral alternatives for patients with dyslipidaemia. ABSTRACT Introduction Dyslipidaemia
Tamer Hodrob, Reem J. Saad, Aya Hamdy, Mariam Saleh Alheneedy, Ahmed Mohamed Shehata Abdelfattah Elsayed, Elsaghir Ghazy, Hazem Ayesh   +6 more
wiley   +1 more source

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

Lipids in Health and Disease, 2017
Background Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal
Tamio Teramoto, Akira Kondo, Arihiro Kiyosue, Mariko Harada-Shiba, Yasushi Ishigaki, Kimimasa Tobita, Yumiko Kawabata, Asuka Ozaki, Marie T. Baccara-Dinet, Masataka Sata   +9 more
doaj   +1 more source

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study

Atherosclerosis Plus, 2021
Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials.
Marina Blanco-Ruiz, Laura Amaya-Pascasio, Reyes de Torres Chacón, María Josefa Álvarez Soria, Antonio Arjona-Padillo, María Magdalena Carrillo Bailén, Rodrigo Milán Pinilla, Irene Pérez Ortega, Belén Sánchez Rodríguez, Luis Andrade Zumárraga, Roberto Valverde Moyano, Manuel Payán Ortiz, Alba María Castillo Fernández, Cristina Del Toro Pérez, Pablo González Bustos, Eduardo Agüera Morales, Purificación Sánchez López, Beatriz Hidalgo Martín, Ricardo Roa Chamorro, Javier Fernández Pérez, María Victoria Mejías Olmedo, Patricia Martínez-Sánchez   +21 more
doaj   +1 more source

An Investigation of the Factors Reducing the Use of Hospital Services: A Systematic Review

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims Hospital service utilization has declined in many health systems due to policy shifts, limited resources, and alternative care approaches. This study aimed to systematically review the factors contributing to a reduction in the use or volume of hospital services.
Sedighe Sadat Tabatabaei Far, Majid Alizadeh, Erfan Kharazmi, Zahra Kavosi   +3 more
wiley   +1 more source

Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES

American Journal of Preventive Cardiology
Background: Patients with recent acute coronary syndrome (ACS) commonly experience chest pain, which affects quality of life even when not due to recurrence of ACS.
Gregory P. Geba, Ruifeng Chen, Kasturi Talapatra, Taylor Brackin, Kusha A. Mohammadi, Robert Pordy, Garen Manvelian, David J. Maron, Gregory G. Schwartz, Michael Szarek, Ph. Gabriel Steg, Sergio Fazio   +11 more
doaj   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies) [PDF]

, 2016
We assessed the safety and tolerability of ascending single doses of alirocumab in healthy Japanese subjects and evaluated the effect of alirocumab at 3 doses (50, 75, 150 mg) on low-density lipoprotein cholesterol (LDL-C) reduction in patients with ...
Kobayashi, Masahiko, Inoue, Satoshi, Uno, Kiyoko, Matsuoka, Osamu, Sugimoto, Masayuki, Minami, Fumiko, Baccara-Dinet, Marie Thérèse, Teramoto, Tamio, Takagi, Yoshiharu   +8 more
core   +1 more source

Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

JACC: Case Reports, 2020
A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury.
June K. Pickett, MD, Maulin Shah, MD, Michael Gillette, PharmD, Peter Jones, MD, Salim Virani, MD, PhD, Christie Ballantyne, MD, Vijay Nambi, MD, PhD   +6 more
doaj   +1 more source